A recent study published in the Journal of Internal Medicine suggests that aspirin may help detect early asymptomatic bladder cancer. Researchers analyzed data from 50,771 Danish adults who began taking aspirin from 2005 to 2023, alongside 156,191 individuals who started non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs). Results showed that those initiating aspirin treatment underwent more cystoscopies—a procedure allowing doctors to view the bladder—compared to those who never used aspirin or NSAIDs. While bladder cancer prevalence was similar among aspirin users, they exhibited a lower prevalence of invasive cancer stages at diagnosis. This indicates that aspirin users may represent a population with a higher incidence of bladder cancer, and their increased cystoscopy rates reflect a warranted clinical response. Conversely, NSAID users had more cystoscopies but a lower prevalence of bladder cancer, suggesting their procedures may not have been clinically justified. These findings underscore the importance of monitoring bladder cancer symptoms in patients starting aspirin therapy and raise questions about aspirin's potential role in bladder cancer prevention.